Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Aug 17, 2021
Notification of investor webinar
Aug 05, 2021
Phase 3 enrolment successfully completed, results in Q4 2021
Jul 30, 2021
Q2 2021 quarterly activity and cash flow report
Jun 28, 2021
Change of Director's Interest Notice
Jun 22, 2021
Results of Meeting
Jun 22, 2021
AGM Chairman's Address and CEO Presentation
Jun 16, 2021
Change of Director's Interest Notice
Jun 15, 2021
Investor presentation, 15 June 2021
Jun 15, 2021
Initial Director's Interest Notice
Jun 15, 2021
Neuren CEO Jon Pilcher appointed to board of directors
Previous
1
2
3
4
5
6
Next